GPP
NXTC icon

Great Point Partners’s NextCure NXTC Stock Holding History

Great Point Partners’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-83,306
Closed -$21.4M – 40
2020
Q2 		$21.4M Sell
83,306
-26,107
-24% -$9.94M 1.71% 18
2020
Q1 		$48.7M Buy
109,413
+14,864
+16% +$7.94M 5.09% 8
2019
Q4 		$63.9M Buy
+94,549
New +$47.4M 5.56% 5

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Great Point Partners's NXTC Position: Q3 2020 in Review

Great Point Partners sold out of NextCure (NXTC) in Q3 2020, closing a stake of 83,306 shares — an estimated $21.4M sold.

Great Point Partners first reported a position in NXTC in Q4 2019 and held it in 3 quarters. The position peaked at $63.9M in Q4 2019. 75 funds tracked by Wall St. Rank hold NXTC as of Q3 2020.

  • Great Point Partners reported no remaining NextCure position as of Q3 2020 after selling out during the quarter.
  • Great Point Partners sold 83,306 NextCure shares in Q3 2020, an estimated $21.4M.
  • Great Point Partners first reported a position in NextCure in Q4 2019 and held it in 3 quarters.
  • Great Point Partners's NextCure position peaked at $63.9M in Q4 2019.
  • 75 funds tracked by Wall St. Rank held NextCure as of Q3 2020.

Based on Great Point Partners's 13F filing for Q3 2020, filed 16 Nov 2020.